Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vanda ( (VNDA) ) has issued an announcement.
On December 30, 2025, Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration approved NEREUS™ (tradipitant), an oral NK-1 receptor antagonist, for the prevention of vomiting induced by motion in adults, marking the first new pharmacologic treatment for motion sickness in more than 40 years and underscoring the company’s position in addressing large, underserved patient populations. The approval, supported by three pivotal clinical trials showing more than 50–70% risk reductions in vomiting compared with placebo and a favorable safety profile for acute use, positions NEREUS™ to address a substantial global market of motion sickness sufferers and validates NK-1 antagonism as a platform mechanism that Vanda is already leveraging in late-stage programs for gastroparesis and for managing nausea and vomiting associated with GLP-1 receptor agonists, with implications for both general travel-related health and military operational readiness.
The most recent analyst rating on (VNDA) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Vanda stock, see the VNDA Stock Forecast page.
Spark’s Take on VNDA Stock
According to Spark, TipRanks’ AI Analyst, VNDA is a Neutral.
The score is held back primarily by deteriorating profitability and elevated cash burn despite a strong, low-debt balance sheet. Technicals are supportive with the stock trading above major moving averages and positive MACD, though momentum is close to overbought. Valuation remains challenged due to negative earnings, while the earnings call provided a moderately positive backdrop from revenue growth, guidance, and upcoming regulatory catalysts.
To see Spark’s full report on VNDA stock, click here.
More about Vanda
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies for patients with high unmet medical needs, including NEREUS™ (tradipitant), a neurokinin-1 receptor antagonist licensed from Eli Lilly and Company that is being advanced for multiple vomiting- and nausea-related indications such as gastroparesis and treatment-related side effects in obesity and diabetes care.
Average Trading Volume: 1,042,854
Technical Sentiment Signal: Hold
Current Market Cap: $425.5M
For a thorough assessment of VNDA stock, go to TipRanks’ Stock Analysis page.